IL15 and neoplasm: Torque’s Deep-PrimedTM cell therapy platform uses novel cell process engineering to generate cytotoxic T lymphocytes (CTLs) that target multiple tumor antigens and that are tethered to Deep-IL15, a crosslinked multimer of human IL15-Fc,to deliver directed immune activation in the tumor microenvironment.